Literature DB >> 33022810

SARS-CoV-2 triggered Takotsubo in 38 patients.

Josef Finsterer1, Claudia Stöllberger1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33022810      PMCID: PMC7675589          DOI: 10.1002/jmv.26581

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
To the Editor, Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) predominantly affects the lungs but direct or indirect involvement of other organs is increasingly recognized. There are a number of publications available showing that in addition to the lungs, the urinary, cardiovascular, gastrointestinal, hematological, hematopoietic, neurological, or reproductive systems may be affected. Cardiac involvement reported in SARS‐CoV‐2 infected patients includes myocardial infarction, myocarditis, heart failure, ventricular arrhythmias, or cardiogenic shock. , , Additionally, there is increasing evidence that also Takotsubo syndrome (TTS) may be a complication of the viral infection. TTS, also known as stress cardiomyopathy, broken heart syndrome, or stunned myocardium, is characterized by transient hypokinesia/dyskinesia/akinesia of the left ventricular myocardium leading to systolic dysfunction. TTS is believed to be triggered by excessive catecholamine release and overstimulation of myocardial adrenergic receptors. TTS predominantly affects females and is triggered by physical respectively emotional stress in one‐third of the cases each. Depending on the location of dyskinesia/akinesia/hypokinesia, four types of TTS are delineated: the apical type, the mid‐ventricular type, the basal type, and the global type. TTS mimics myocardial infarction clinically, chemically, and electrocardiographically. Clinical manifestations of TTS include anginal chest pain and dyspnea. Creatine‐kinase, troponin, catecholamines and proBNP are frequently elevated. Electrocardiography shows ST‐elevation and negative T‐waves. However, coronary angiography is usually normal. TTS is diagnosed according to the Mayo Clinic criteria. The outcome of TTS is usually fair and more favorable in TTS triggered by emotional than by physical stress. Though generally believed to be a rare complication of the SARS‐CoV‐2 infection, 38 cases with SARS‐CoV‐2 associated TTS have been reported so far (Table 1). , , , , , , , , , , , , , The first patient with TTS associated with a SARS‐CoV‐2 infection was a 83‐year‐old Swiss female described by Meyer et al. Since then, several other SARS‐CoV‐2 infected patients with TTS have been reported. In a patient reported by Chadha et al. TTS was triggered by the fear from becoming infected without being actually infected with SARS‐CoV‐2. This patient was not included in the current evaluation. Also the patient reported by Kir et al. was not included as echocardiography was normal throughout hospitalization.
Table 1

Patients with SARS‐CoV‐2‐associated TTS so far reported

Age (year) Sex OC TTST Treatment Outcome Origin Reference
83FTClassicalHeart failure therapyRecoverySwissMeyer et al. 8
67FBClassicalPericardio‐centesisRecoveryUSDabbagh et al. 9
48FBClassicalDobutamineImprovementUSMinhas et al. 10
71FTMid‐ventricularnrnrBelgiumNguyen et al. 11
87FBClassicalBisoprolol, heparinRecoveryItalyRoca et al. 12
59FBClassicalBB, DR, nitrateRecoveryItalyModerato et al. 13
39–65M (n = 5)BClassical (n = 4),nrRecovery (n = 3)USGiustino et al. 14
Basal (n = 1)Death (n = 2)
84MBClassicalASS, nitro, BB,RecoveryItalyPasqualetto et al. 15
85FBClassicalASS, inotropesDeathItalyPasqauletto et al. 15
81MBClassicalASS, BB, heparinRecoveryItalyPasqualetto et al. 15
52MBClassicalHeparin, tocilizumabRecoveryUSTaza et al. 16
nr n = 19nrnrnrnrEuropeDweck et al. 17
59FBMid‐ventricularVentilation, lidocaineRecoveryUSTsao et al. 5
50MBBasalnrRecoverySpainSolano‐López et al. 18
72FBClassicalASS, statinsDeathUSTheetha Kariyanna et al. 19
67FBClassicalDAPT, statins, OACRecoveryUSSattar et al. 20

Abbreviations: A, after TTS; B, before TTS; BB, beta‐blocker; COVID‐19, coronavirus disease 2019; DAPT, dual antiplatelet treatment; DR, diuretics; nr, not reported; OAC, oral anticoagulation; OC, onset of COVID‐19; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; T, together with TTS; TTS, Takotsubo syndrome; TTST, TTS‐type.

Patients with SARS‐CoV‐2‐associated TTS so far reported Abbreviations: A, after TTS; B, before TTS; BB, beta‐blocker; COVID‐19, coronavirus disease 2019; DAPT, dual antiplatelet treatment; DR, diuretics; nr, not reported; OAC, oral anticoagulation; OC, onset of COVID‐19; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; T, together with TTS; TTS, Takotsubo syndrome; TTST, TTS‐type. In 17 patients, TTS developed after onset of the SARS‐CoV‐2 infection, in two patients together with the infection, and in 19 patients onset of TTS was not reported (Table 1). Age ranged between 39 and 87 years among 19 patients. In 19 patients age was not reported. Ten patients were females, 9 were males, and in 19 patients gender was not reported. Fifteen patients presented with the classical type, two with the mid‐ventricular type of TTS, and two patients with the basal type. In 19 patients, the TTS type was not reported (Table 1). Treatment for TTS was quite variable but most patients received beta‐blockers, diuretics, heparin, or acetyl‐salicylic acid (Table 1). Only a single patient received oral anticoagulation. One patient required pericardio‐centesis because of immune‐mediated pericarditis. Thirteen patients recovered, four died, one patient improved, and in 20 patients the outcome was not reported (Table 1). Twenty‐seven patients originated from Europe and 11 from the US. This mini‐review shows that TTS can be associated with the SARS‐CoV‐2 infection but whether this association is accidental or causal remains speculative. There are indications that the general prevalence of SARS‐CoV‐2 associated TTS is not increased compared to the pre‐COVID‐10 era as reported by Jabri et al. and Delmas et al. Clinical presentation, epidemiology, treatment, and outcome of SARS‐CoV‐2‐associated TTS is similar to COVID‐19‐unrelated TTS. In some patients, as reported by Sala et al., TTS may mimic myocarditis. TTS should be suspected in a SARS‐CoV‐2 infected patient if symptoms and signs of a myocardial infarction or heart failure develop in addition to the pulmonary compromise. In conclusion, TTS in the context of a SARS‐CoV‐2 infection is more frequent than anticipated. Whether the general prevalence of TTS is truly increased compared with non‐COVID‐19 times requires further investigations.

AUTHOR CONTRIBUTIONS

Josef Finsterer: design, literature search, discussion, first draft, and critical comments. Claudia Stöllberger: literature search, discussion, and critical comments.

KEYWORDS

coronavirus, SARS‐Cov‐2, stress cardiomyopathy, stunned myocardium
  20 in total

1.  Long-Term Prognosis of Patients With Takotsubo Syndrome.

Authors:  Jelena R Ghadri; Ken Kato; Victoria L Cammann; Sebastiano Gili; Stjepan Jurisic; Davide Di Vece; Alessandro Candreva; Katharina J Ding; Jozef Micek; Konrad A Szawan; Beatrice Bacchi; Rahel Bianchi; Rena A Levinson; Manfred Wischnewsky; Burkhardt Seifert; Susanne A Schlossbauer; Rodolfo Citro; Eduardo Bossone; Thomas Münzel; Maike Knorr; Susanne Heiner; Fabrizio D'Ascenzo; Jennifer Franke; Annahita Sarcon; L Christian Napp; Milosz Jaguszewski; Michel Noutsias; Hugo A Katus; Christof Burgdorf; Heribert Schunkert; Holger Thiele; Johann Bauersachs; Carsten Tschöpe; Burkert M Pieske; Lawrence Rajan; Guido Michels; Roman Pfister; Alessandro Cuneo; Claudius Jacobshagen; Gerd Hasenfuß; Mahir Karakas; Wolfgang Koenig; Wolfgang Rottbauer; Samir M Said; Ruediger C Braun-Dullaeus; Adrian Banning; Florim Cuculi; Richard Kobza; Thomas A Fischer; Tuija Vasankari; K E Juhani Airaksinen; Grzegorz Opolski; Rafal Dworakowski; Philip MacCarthy; Christoph Kaiser; Stefan Osswald; Leonarda Galiuto; Filippo Crea; Wolfgang Dichtl; Klaus Empen; Stephan B Felix; Clément Delmas; Olivier Lairez; Ibrahim El-Battrawy; Ibrahim Akin; Martin Borggrefe; John Horowitz; Martin Kozel; Petr Tousek; Petr Widimský; Ekaterina Gilyarova; Alexandra Shilova; Mikhail Gilyarov; David E Winchester; Christian Ukena; Jeroen J Bax; Abhiram Prasad; Michael Böhm; Thomas F Lüscher; Frank Ruschitzka; Christian Templin
Journal:  J Am Coll Cardiol       Date:  2018-08-21       Impact factor: 24.094

2.  Collateral damage: Fear from SARS-CoV2-infection causing Takotsubo cardiomyopathy.

Authors:  Tobias Uhe; Andreas Hagendorff; Rolf Wachter; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2020-07-13       Impact factor: 5.460

3.  Cardiac Tamponade Secondary to COVID-19.

Authors:  Mohammed F Dabbagh; Lindsey Aurora; Penny D'Souza; Allison J Weinmann; Pallavi Bhargava; Mir B Basir
Journal:  JACC Case Rep       Date:  2020-04-23

Review 4.  Coronavirus Disease 2019 and the Myocardium.

Authors:  José Albuquerque de Figueiredo Neto; Fabiana G Marcondes-Braga; Lidia Zytinski Moura; André Melo E Silva de Figueiredo; Viviane Melo E Silva de Figueiredo; Ricardo Mourilhe-Rocha; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2020-07-03       Impact factor: 2.000

5.  COVID-19-Associated Stress (Takotsubo) Cardiomyopathy.

Authors:  Connie W Tsao; Jordan B Strom; James D Chang; Warren J Manning
Journal:  Circ Cardiovasc Imaging       Date:  2020-07-15       Impact factor: 7.792

6.  A case of Takotsubo cardiomyopathy with COVID 19.

Authors:  Damien Nguyen; Thomas Nguyen; David De Bels; José Castro Rodriguez
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-09-01       Impact factor: 6.875

Review 7.  Extrapulmonary complications of COVID-19: A multisystem disease?

Authors:  Kenneth I Zheng; Gong Feng; Wen-Yue Liu; Giovanni Targher; Christopher D Byrne; Ming-Hua Zheng
Journal:  J Med Virol       Date:  2020-07-22       Impact factor: 20.693

8.  Takotsubo Syndrome Associated with COVID-19.

Authors:  Elena Roca; Carlo Lombardi; Marco Campana; Oscar Vivaldi; Barbara Bigni; Bruno Bertozzi; Giovanni Passalacqua
Journal:  Eur J Case Rep Intern Med       Date:  2020-04-21
View more
  7 in total

1.  Consider affection of respiratory muscles in SARS-CoV-2 related polyradiculitis with coughing but normal inflammatory markers.

Authors:  Josef Finsterer
Journal:  Ann Med Surg (Lond)       Date:  2022-09-01

2.  nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis.

Authors:  Ajay Prakash; Harvinder Singh; Phulen Sarma; Anusuya Bhattacharyya; Deba Prasad Dhibar; Neeraj Balaini; Ritu Shree; Manoj Goyal; Manish Modi; Bikash Medhi
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

3.  Broken Heart (Takotsubo) Syndrome Triggered by SARS-CoV-2.

Authors:  Josef Finsterer
Journal:  SN Compr Clin Med       Date:  2021-01-12

Review 4.  A review of ischemic stroke in COVID-19: currently known pathophysiological mechanisms.

Authors:  Xuhuan Tang; Fang Zheng
Journal:  Neurol Sci       Date:  2021-10-21       Impact factor: 3.830

Review 5.  Cardiac involvement in the long-term implications of COVID-19.

Authors:  Benjamin A Satterfield; Deepak L Bhatt; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2021-10-22       Impact factor: 49.421

Review 6.  Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19.

Authors:  Rhian M Touyz; Marcus O E Boyd; Tomasz Guzik; Sandosh Padmanabhan; Linsay McCallum; Christian Delles; Patrick B Mark; John R Petrie; Francisco Rios; Augusto C Montezano; Robert Sykes; Colin Berry
Journal:  CJC Open       Date:  2021-06-16

7.  Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.

Authors:  Samir Abu-Rumeileh; Ahmed Abdelhak; Matteo Foschi; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2020-08-25       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.